natgillin/translations-raw huggingface dataset:
TachoSil was more effective than the argon beamer at stopping blood flow during liver surgery.
Pri operativnem posegu na jetrih je bilo v primerjavi z argonskim plazemskim koagulatorjem zdravilo TachoSil bolj učinkovito pri zaustavitvi toka krvi.
In the first study, the average time until bleeding stopped was 3.9 minutes with TachoSil compared with 6.3 minutes with the argon beamer, and in the second study, these values were 3.6 and 5.0 minutes, respectively.
V prvi študiji je bil povprečen čas, potreben za zaustavitev krvavitve, pri uporabi zdravila TachoSil 3, 9 minut, ob uporabi argonskega plazemskega koagulatorja pa 6, 3 minute, medtem ko so bile v drugi študiji te vrednosti 3, 6 in 5, 0 minut.
TachoSil was more effective than stitching in the kidney surgery patients.
Pri bolnikih, operiranih na ledvicah, je bilo zdravilo TachoSil bolj učinkovito kot šivanje.
The first study looking at lung surgery patients was not sufficient to support the use of TachoSil in sealing tissue, because very few patients in the study had any air leakage.
Prva študija na bolnikih, operiranih na pljučih ni zadoščala za podporo uporabe zdravila TachoSil za zapiranje tkiva, saj so pri zelo malo bolnikih iz študije zaznali kakršno koli uhajanje zraka.
However, in the second study, which involved 301 patients, it took an average of 15.3 hours for leakage to stop with TachoSil compared with 20.5 hours with standard techniques.
Vendar pa je bil v drugi študiji, v kateri je sodeloval 301 bolnik, čas, potreben za zaustavitev puščanja, v povprečju 15, 3 ure z zdravilom TachoSil v primerjavi z 20, 5 ure pri standardnih tehnikah.
TachoSil was also more effective than standard materials at stopping bleeding during surgery on the heart or blood vessels.
Zdravilo TachoSil je bilo bolj učinkovito kot standardni materiali pri zaustavljanju krvavitve med operacijo na srcu ali krvnih žilah.
After three minutes, bleeding had stopped in 75% of the patients treated with TachoSil (44 out of 59), compared with 33% of those treated with standard techniques (20 out of 60).
Po treh minutah se je krvavitev ustavila pri 75% bolnikov, zdravljenih z zdravilom TachoSil (44 od 59), v primerjavi s 33% tistih, zdravljenih s standardnimi tehnikami (20 od 60).
Thromboembolic complications (blood clots) may occur if TachoSil is unintentionally applied inside a blood vessel.
Če se zdravilo TachoSil nenamerno uporabi v krvni žili, lahko nastanejo tromboembolični zapleti (krvni strdki).
As for other sealants, TachoSil may cause an allergic reaction.
Kot druga sredstva za zapiranje tkiva lahko tudi zdravilo TachoSil povzroči alergijske reakcije.
In rare cases, patients may also develop antibodies to the proteins in TachoSil, which could interfere with blood clotting.
Za beljakovine zdravila TachoSil se lahko v redkih primerih pri bolniku pojavijo protitelesa, ki lahko ovirajo strjevanje krvi.
The most common side effect with TachoSil (seen in between 1 and 10 patients in 100) is pyrexia (fever).
Najpogostejši neželeni učinek zdravila TachoSil (opažen pri 1 do 10 bolnikih izmed 100), je pireksija (vročina).
For the full list of all side effects reported with TachoSil, see the Package Leaflet.
Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila TachoSil, glejte navodilo za uporabo.
TachoSil should not be used in people who may be hypersensitive (allergic) to fibrinogen, thrombin or any of the other ingredients.
Zdravila TachoSil ne smejo uporabljati osebe, ki utegnejo biti preobčutljive za (alergične na) fibrinogen, trombin ali katero koli drugo sestavino zdravila.
TachoSil has not been studied in neurosurgery (surgery on the nervous system, including the brain) or surgery to connect up two sections of the gut, such as a stomach bypass.
Zdravila TachoSil niso proučevali z vidika nevrokirurgije (kirurgija živčnega sistema, vključno z možgani) ali kirurškega posega za povezavo dveh delov črevesa, kot je želodčni obvod.
The Committee for Medicinal Products for Human Use (CHMP) decided that TachoSil’ s benefits are greater than its risks for supportive treatment in surgery for the improvement of haemostasis, to promote tissue sealing and for suture support in vascular surgery where standard techniques are insufficient.
Odbor za zdravila za uporabo v humani medicini (CHMP) je zaključil, da so koristi zdravila TachoSil pri podpornem zdravljenju v kirurgiji za izboljšanje hemostaze, za pospeševanje zapiranja tkiva in za podporo šivom v žilni kirurgiji, takrat ko standardne tehnike ne zadoščajo, večje od z njim povezanih tveganj.
The Committee recommended that TachoSil be given marketing authorisation.
Odbor je priporočil, da se za zdravilo TachoSil odobri dovoljenje za promet.
Other information about TachoSil:
Druge informacije o zdravilu TachoSil:
The European Commission granted a marketing authorisation valid throughout the European Union for TachoSil to Nycomed Austria GmbH on 8 June 2004.
Evropska komisija je dovoljenje za promet z zdravilom TachoSil, veljavno po vsej Evropski uniji, odobrila družbi Nycomed Austria GmbH dne 8. junija 2004.
The full EPAR for TachoSil is available here.
Celotno evropsko javno poročilo o oceni zdravila (EPAR) za zdravilo TachoSil je na voljo tukaj.
This summary was last updated in 01-2009.
Ta povzetek je bil nazadnje posodobljen 01- 2009.
Package size
Pot uporabe
TachoSil
Ovojnina
1 sponge of 9.5 x 4.8 cm
Velikost pakiranja
2 sponges of 4.8 x 4.8 cm
Medicirana gobica Medicirana gobica Medicirana gobica Medicirana gobica
1 sponge of 3.0 x 2.5 cm
Lokalno Lokalno Lokalno Lokalno
Blister (alu)
Pretisni omot (alu) Pretisni omot (alu) Pretisni omot (alu) Pretisni omot (alu)
5 sponges of 3.0 x 2.5 cm
1 gobica 9, 5 x 4, 8 cm 2 gobici 4, 8 x 4, 8 cm 1 gobica 3, 0 x 2, 5 cm 5 gobic 3, 0 x 2, 5 cm
TachoSil medicated sponge.
TachoSil zdravilna gobica
Qualitative and Quantitative composition:
Kakovostna in količinska sestava:
TachoSil contains per cm2:
TachoSil na cm2 vsebuje:
Human Fibrinogen Human Thrombin
humani fibrinogen 5, 5 mg humani trombin 2, 0 i. e.
Medicated sponge TachoSil is an off-white sponge.
Zdravilna gobica.
The active side of the sponge, which is coated with fibrinogen and thrombin, is marked by a yellow colour.
Učinkovita stran gobice, ki je obložena s fibrinogenom in trombinom, je označena z rumeno barvo.
TachoSil is indicated for supportive treatment in surgery for improvement of haemostasis, to promote tissue sealing, and for suture support in vascular surgery where standard techniques are insufficient (see section 5.1).
TachoSil je namenjen podpornemu zdravljenju v kirurgiji za izboljšanje hemostaze - pospešuje zatesnitev tkiv, in za podporo šivanja v žilni kirurgiji, kjer ne zadoščajo standardne kirurške tehnike (glejte poglavje 5. 1).
Posology The use of TachoSil is restricted to experienced surgeons.
Odmerjanje Uporaba TachoSila je omejena na izkušene kirurge.
There is insufficient information for use in paediatric patients.
Za uporabo pri pediatričnih bolnikih ni na voljo zadostnih informacij.
The number of TachoSil sponges to be applied should always be oriented towards the underlying clinical need for the patient.
Pri določanju števila gobic TachoSila za uporabo se je potrebno ravnati po osnovni klinični potrebi bolnika.
The number of TachoSil sponges to be applied is governed by the size of the wound area.
Število gobic TachoSila, ki jih uporabite, je odvisno od velikosti poškodovane površine.
Application of TachoSil must be individualised by the treating surgeon.
Lečeči kirurg mora prilagoditi uporabo TachoSila pri posamezniku.
In clinical trials, the individual dosages have typically ranged from 1-3 sponges (9.5 cm x 4.8 cm); application of up to 7 sponges has been reported.
Pri kliničnih preskušanjih so običajno uporabili 1- 3 gobice (9, 5 cm x 4, 8 cm); poročali so o uporabi do 7 gobic.
For smaller wounds, e. g. in minimal invasive surgery the smaller size sponges (4.8 cm x 4.8 cm or 3.0 cm x 2.5 cm) are recommended.
Za manjše rane, npr. pri minimalno invazivnem kirurškem posegu, priporočamo manjšo velikost gobic (4, 8 cm x 4, 8 cm ali 3, 0 cm x 2, 5 cm).
Method and route of administration For local use only.
Način in pot uporabe Samo za lokalno uporabo.
See section 6.6 for more detailed instructions.
Za podrobnejša navodila glejte poglavje 6. 6.
2 4.4 Special warnings and precautions for use
2 Samo za lokalno uporabo.
Specific data have not been obtained on the use of this product in neurosurgery or in gastrointestinal anastomoses surgery.
Za uporabo tega zdravila v nevrokirurgiji ali gastrointestinalni anastomozni kirurgiji ni bilo pridobljenih specifičnih podatkov.
Life threatening thromboembolic complications may occur if the preparation is unintentionally applied intravascularly.
Če se zdravilo pomotoma uporabi intravaskularno, se lahko pojavijo življenjsko ogrožajoči trombembolični zapleti.
As with any protein product, allergic type hypersensitivity reactions are possible.
Kot pri vsakem proteinskem izdelku, so možne alergijske preobčutljivostne reakcije.
Signs of hypersensitivity reactions include hives, generalised urticaria, tightness of the chest, wheezing, hypotension and anaphylaxis.
Znaki preobčutljivostnih reakcij vključujejo koprivnico, generalizirano urtikarijo, občutek tesnobe v prsih, sopihanje, hipotenzijo in anafilaksijo.
If these symptoms occur, the administration has to be discontinued immediately.
Če se ti simptomi pojavijo, je treba takoj prenehati z uporabo.
Standard measures to prevent infections resulting from the use of medicinal products prepared from human blood or plasma include selection of donors, screening of individual donations and plasma pools for specific markers of infection and the inclusion of effective manufacturing steps for the inactivation/ removal of viruses.
Standardni ukrepi za preprečevanje okužb, ki so posledica uporabe zdravil, pripravljenih iz humane krvi ali plazme, vključujejo izbiro darovalcev, pregledovanje posameznih darovanj in zbirov plazme na specifične markerje infekcije in vključitev učinkovitih korakov izdelave za inaktivacijo/ odstranitev virusov.
Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded.
Kljub temu pri uporabi zdravil, pripravljenih iz humane krvi ali plazme, ni mogoče povsem izključiti možnosti prenosa povzročiteljev okužb.
This also applies to unknown or emerging viruses and other pathogens.
To velja tudi za neznane ali nove viruse in druge patogene organizme.
The measures taken are considered effective for enveloped viruses such as HIV, HBV and HCV and for the non-enveloped virus HAV.
Ti ukrepi so učinkoviti za viruse z ovojnico kot so HIV, HBV in HCV ter za virus brez ovojnice HAV.
The measures taken may be of limited value against non-enveloped viruses such as parvovirus B19.
Uvedeni ukrepi pa imajo lahko le omejeno vrednost proti virusom brez ovojnice, kot je parvovirus B19.
Parvovirus B19 infection may be serious for pregnant women (fetal infection) and for individuals with immunodeficiency or increased erythropoiesis (e. g. haemolytic anaemia).
Infekcija s parvovirusom B19 lahko resno ogroža nosečnice (okužba ploda) in posameznike z imunsko pomanjkljivostjo ali povečano eritropoezo (npr. hemolitična anemija).
It is strongly recommended that every time that TachoSil is administered to a patient, the name and batch number of the product are recorded in order to maintain a link between the patient and the batch of the product.
Zelo priporočljivo je, da se pri vsaki uporabi TachoSila pri bolniku zabeležita ime in serijska številka zdravila, za ohranitev povezave med bolnikom in serijo zdravila.
No formal interaction studies have been performed.
Formalne študije o medsebojnem delovanju niso bile opravljene.
Similar to comparable products or thrombin solutions, the sealant may be denaturated after exposure to solutions containing alcohol, iodine or heavy metals (e. g. antiseptic solutions).
Podobno kot primerljiva zdravila ali raztopine trombina se lahko to sredstvo za zapiranje ran po izpostavitvi raztopinam, ki vsebujejo alkohol, jod ali težke kovine (npr. antiseptične raztopine), denaturira.
Such substances should be removed to the greatest possible extent before applying the sealant.
Takšne snovi moramo v največji možni meri odstraniti pred namestitvijo sredstva za zapiranje ran.
The safety of TachoSil for use in human pregnancy or breastfeeding has not been established in controlled clinical trials.
Varnost uporabe TachoSila med nosečnostjo ali dojenjem pri ljudeh ni bila ugotovljena v kontroliranih kliničnih preskušanjih.
Experimental animal studies are insufficient to assess the safety with respect to reproduction, development of the embryo or foetus, the course of gestation and peri- and postnatal development.
Poskusne študije na živalih ne zadoščajo za oceno varnosti glede razmnoževanja, razvoja zarodka ali ploda, poteka nosečnosti ter peri - in postnatalnega razvoja.
Therefore, TachoSil should be administered to pregnant and lactating women only if clearly needed.
Zato smejo noseče in doječe ženske zdravilo TachoSil uporabljati samo, če je nujno potrebno.
Hypersensitivity or allergic reactions (which may include angioedema, burning and stinging at the application site, bronchospasm, chills, flushing, generalised urticaria, headache, hives, hypotension, lethargy, nausea, restlessness, tachycardia, tightness of the chest, tingling, vomiting, wheezing) may occur in rare cases in patients treated with fibrin sealants/ haemostatics.
Preobčutljivostne ali alergijske reakcije (ki lahko vključujejo angioedem, pekoč občutek in zbadanje na mestu aplikacije, bronhospazem, mrzlico, rdečico, generalizirano urtikarijo, glavobol, koprivnico, hipotenzijo, letargijo, slabost, nemir, tahikardijo, tiščanje v prsih, mravljinčanje, bruhanje, piskajoče dihanje) se lahko v redkih primerih pojavijo pri bolnikih, ki jih zdravimo s fibrinskimi/ hemostatičnimi sredstvi za zapiranje ran.
Such reactions may especially be seen, if the preparation is applied repeatedly, or administered to patients known to be hypersensitive to constituents of the product.
3 Takšne reakcije lahko vidimo zlasti, če se zdravilo namešča večkrat ali bolnikom, za katere je znano, da so preobčutljivi za sestavine zdravila.
Antibodies against components of fibrin sealant/ haemostatic products may occur rarely.
Redko se laho pojavijo protitelesa proti sestavinam fibrinskih/ hemostatičnih zdravil za zapiranje ran.
Thromboembolic complications may occur if the preparation is unintentionally applied intravascularly (see section 4.4).
Če se zdravilo pomotoma uporabi intravaskularno, se lahko pojavijo trombembolični zapleti (glejte poglavje 4. 4).
For viral safety see section 4.4
Za varnost pred virusi glejte poglavje 4. 4.
Frequency of undesirable effects for TachoSil based on all adverse event data from six clinical trials, two post-authorisation safety studies and spontaneous reporting.
Pogostnost neželenih učinkov zdravila TachoSil temelji na podatkih o vseh neželenih dogodkih iz šestih kliničnih raziskav, dveh študij o varnosti zdravila po odobritvi dovoljenja za promet in spontanih poročil.
Summary of the safety profile The safety data of TachoSil generally reflect the type of post-operative complications related to the surgical settings in which the trials were conducted and the underlying disease of the patients.
Povzetek varnostnega profila Podatki o varnosti zdravila TachoSil v splošnem odražajo vrsto pooperativnih zapletov, ki so povezani s kirurškim okoljem, v katerem so raziskave potekale, in osnovnimi boleznimi bolnikov.
Tabulated summary of adverse reactions Data from the six controlled clinical trials conducted by the MAH has been pooled into an integrated dataset and the frequencies of occurrence in this SmPC originate from this integrated dataset.
Tabeliran povzetek neželenih reakcij Podatke iz šestih kontroliranih kliničnih raziskav, ki jih je opravil imetnik dovoljenja za promet z zdravilom, so združili v skupen nabor podatkov, iz katerega izhajajo pogostnosti pojavljanja v tem Povzetku glavnih značilnosti zdravila.
In the integrated analyses, 521 patients were treated with TachoSil and 511 patients were treated with comparator treatment.
V združeni analizi je bilo 521 bolnikov zdravljenih z zdravilom TachoSil, 511 pa s primerjalnim zdravljenjem.
Due to practical reasons (comparison to standard surgical and standard haemostatic treatment), blinding was not possible in the TachoSil trials.
Zaradi praktičnih razlogov (primerjava s standardnim kirurškim in standardnim hemostatskim zdravljenjem) z zdravilom TachoSil ni bilo mogoče opraviti slepih raziskav.
Therefore the studies were performed as open-label studies.
Raziskave so bile torej opravljene kot odprto- označene raziskave.
The following categories are used to rank the undesirable effects by frequency of occurrence: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000); and very rare (< 1/ 10,000), not known (cannot be estimated from the available data).
Za razvrščanje neželenih učinkov po pogostnosti pojavljanja se uporabljajo naslednje kategorije: zelo pogosto (> 1/ 10); pogosto (> 1/ 100 do < 1/ 10); občasno (> 1/ 1000 do < 1/ 100); redko (> 1/ 10. 000 do < 1/ 1000); in zelo redko (< 1/ 10. 000).
Very rare
(> 1/ 1000 do < 1/ 100) Organski sistem
(≥ 1/ 100 to < 1/ 10)
(≥1/ 100 do < 1/ 10)
(≥ 1/ 1,000 to < 1/ 100)
(< 1/ 10, 000)
(< 1/ 10,000), not known
Bolezni imunskega sistema
Pyrexia*
preobčutljivost
(cannot be estimated from the available data) Thromboembolism (if applied intravascularly)
trombembolizem Žilne bolezni (pri intravaskularni uporabi) Splošne težave in spremembe pireksija * na mestu aplikacije * Pireksija se pojavi pri 6, 3% primerljivim zdravljenjem.
*Pyrexia occurred in 6.3% of the patients treated with TachoSil and in 5.9% of the patients treated with comparator treatment.
bolnikov, ki se zdravijo s TachoSilom in 5, 9% bolnikov zdravljenih s
Local haemostatics, ATC code:
Hemostatiki za lokalno zdravljenje, oznaka ATC:
TachoSil contains fibrinogen and thrombin as a dried coating on the surface of a collagen sponge.
TachoSil vsebuje fibrinogen in trombin kot sušen nanos na površini kolagenske gobice.
At contact with physiological fluids, e. g. blood, lymph or physiological saline solution the components of the coating dissolve and partly diffuse into the wound surface.
Pri stiku s fiziološkimi tekočinami, npr. s krvjo, limfo ali slano fiziološko raztopino, se sestavine nanosa raztopijo in delno razporedijo po površini rane.
This is followed by the fibrinogen- thrombin reaction which initiates the last phase of physiological blood coagulation.
Temu sledi fibrinogensko- trombinska reakcija, ki
Fibrinogen is converted into fibrin monomers which spontaneously polymerise to a fibrin clot, which holds the collagen sponge tightly to the wound surface.
Fibrinogen se pretvori v fibrinske monomere, ki spontano polimerizirajo v fibrinski strdek, ki tesno drži kolagensko gobico na površini rane.
The fibrin is then cross linked by endogenous factor XIII, creating a firm, mechanically stable network with good adhesive properties and provides sealing as well.
Fibrin se nato navzkrižno poveže z endogenim faktorjem XIII in tvori trdno, mehansko stabilno mrežo z dobrimi adhezivnimi lastnostmi, ki omogoči tudi zapiranje rane.
Clinical studies demonstrating haemostasis were conducted in a total of 240 patients (118 TachoSil, 122 argon beamer) undergoing partial liver resection surgery and 185 patients (95 TachoSil, 93 standard surgical treatment) undergoing surgical resection of superficial renal tumour.
V kliničnih študijah za prikaz hemostaze so spremljali skupno 240 bolnikov (118 TachoSil, 122 argonska koagulacija), pri katerih so opravili kirurški poseg delne resekcije jeter in 185 bolnikih (95 TachoSil, 93 standardno kirurško zdravljenje), pri katerih so opravili kirurško resekcijo površinskega ledvičnega tumorja.
A further controlled study in 119 patients (59 TachoSil, 60 haemostatic fleece) demonstrated sealing, haemostasis and suture support in patients undergoing cardiovascular surgery.
Nadaljnja kontrolirana študija na 119 bolnikih (59 TachoSil, 60 hemostatska krpica) je pokazala tesnjenje, hemostazo in podporo šivov pri bolnikih s srčnožilnimi kirurškimi posegi.
Tissue sealing in lung surgery was investigated in two controlled trials in patients undergoing lung surgery.
Tesnenje tkiv pri kirurških posegih na pljučih so preučili z dvema kontroliranima študijama na bolnikih, ki so bili operirani na pljučih.
The first controlled clinical trial investigating tissue sealing in lung surgery failed to document superiority over standard treatment measured by air leakage due to the inclusion of a large group of patients (53%) without air leakage.
V prvem kontroliranem kliničnem preskušanju, v katerem so preiskovali tesnenje tkiva v pljučni kirurgiji, niso dokazali prednosti pred standardnim zdravljenjem, merjenim na osnovi puščanja zraka, ker je bil v študijo vključen velik delež bolnikov (53%) brez puščanja zraka.
However, the second study investigating tissue sealing in 299 patients (148 TachoSil, 151 standard surgical treatment) with demonstrated intraoperative air leakage showed the superiority of TachoSil compared to standard treatment.
Druga študija o tesnjenju tkiv na 299 bolnikih (148 TachoSil, 151 standardno kirurško zdravljenje) z ugotovljenim intraoperativnim puščanjem zraka pa je pokazala, da je TachoSil boljši v primerjavi s standardnim zdravljenjem.
TachoSil is intended for local application only.
TachoSil je namenjen samo za lokalno uporabo.
Intravascular administration is not possible.
Intravaskularna uporaba ni možna.
As a consequence, intravascular pharmacokinetic studies were not performed in man.
Zato na ljudeh niso opravili intravaskularnih farmakokinetičnih študij.
In animal studies TachoSil shows a progressive biodegradation.
Študije TachoSila na živalih so pokazale progresivno biodegradacijo.
The fibrin clot is metabolised in the same way as endogenous fibrin by fibrinolysis and phagocytosis.
Presnova fibrinskega strdka poteka enako kot pri endogenem fibrinu, s fibrinolizo in fagocitozo.
The collagen sponge is degraded by resorptive granulation tissue.
Resorbcijsko granulacijsko tkivo razgradi kolagensko gobico.
Approximately 24 weeks after application only a few remnants were present without any signs of local irritation.
Približno 24 tednov po uporabi je bilo prisotnih le nekaj ostankov, brez kakršnihkoli znakov lokalnega draženja.
Single dose toxicity studies in different species of animals have shown no signs of acute toxic effect.
Študije toksičnosti po enkratnem odmerku pri različnih živalskih vrstah niso pokazale znakov akutnega toksičnega učinka.
Equine collagen Human albumin Riboflavine (E 101) Sodium chloride Sodium citrate L-arginin-hydrochloride.
konjski kolagen humani albumin riboflavin (E 101) natrijev klorid natrijev citrat L- argininijev klorid
Once the foil sachet is opened, TachoSil must be used immediately.
TachoSil je treba uporabiti takoj po odprtju folijske vrečke.
Do not store above 25 °C.
Shranjujte pri temperaturi do 25 oC.
6.5 Nature and contents of container
5 6. 5 Vrsta ovojnine in vsebina
TachoSil is packed in a double packaging:
TachoSil je pakiran v dvojni ovojnini:
- An outer container consisting of an aluminium-bonded foil sachet
- Zunanja ovojnina, narejena iz vrečke iz aluminijaste folije.
- An inner container (sterile) consisting of a polystyrene blister sealed with a peel lacquer-laminate
- Stična ovojnina (sterilna), narejena iz polistirenskega pretisnega omota zaprt s prevleko iz
paper
lakiranega- laminatnega papirja.
- A desiccant bag is included in the outer container
- Sušilna vrečka je nameščena v zunanjo ovojnino.
Each sponge is packed individually.
Vsaka gobica je pakirana posamezno.
Package with 1 sponge of 9.5 cm x 4.8 cm Package with 2 sponges of 4.8 cm x 4.8 cm Package with 1 sponge of 3.0 cm x 2.5 cm Package with 5 sponges of 3.0 cm x 2.5 cm
Pakiranje z 1 gobico velikosti 9, 5 cm x 4, 8 cm Pakiranje z 2 gobicama velikosti 4, 8 cm x 4, 8 cm Pakiranje z 1 gobico velikosti 3, 0 cm x 2, 5 cm Pakiranje s 5 gobicami velikosti 3, 0 cm x 2, 5 cm